![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BeiGene’s Brukinsa Makes Strong Showing in Leukemia Trial
BeiGene’s Brukinsa Makes Strong Showing in Leukemia Trial
![BeiGene logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/BeiGene-logo.gif?t=1621632182&width=430)
BeiGene said its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) showed superior results for leukemia and lymphoma patients over another BTK inhibitor, ibrutinib, in a head-to-head study.
An interim analysis from a phase 3 trial in 415 adult participants with either relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma found that Brukinsa generated a higher overall response vs. ibrutinib, defined as the number of patients having a partial or complete response to treatment.
Patients treated with Brukinsa also had a significantly lower risk of irregular heartbeats when compared against ibrutinib and the treatment was discontinued more frequently in the ibrutinib cohort, according to BeiGene.
Upcoming Events
-
21Oct